Treatment of residual metastases with Na[trans-RuCl4 (DMSO)lm] and ruthenium uptake by tumor cells

Anticancer Drugs. 1996 Aug;7(6):697-702. doi: 10.1097/00001813-199608000-00011.

Abstract

Treatment of MCa mammary carcinoma metastases by i.p. administration of a total dose of 450 mg/kg Na[trans-RuCl4(DMSO)lm], after successful surgical removal of primary tumor mass, causes a significant prolongation of the host's life-time expectancy. This effect, related to lung metastasis inhibition, seems not attributable to a direct inhibition of tumor cells since antimetastatic effects can be achieved also when drug treatment occurs before tumor cell injection into the host. Also, the activity of Na[trans-RuCl4(DMSO)lm] seems independent of its concentration in tumor cells. Rather it must be stressed that the fate of this compound in the blood, following i.v. administration, is fast and only a very low percent of the total dose reaches the tumor target in the lungs. These data emphasize the possibility that Na[trans-RuCl4(DMSO)lm] increases the resistance of the host against metastasis formation, possibly by the already shown mechanism of potentiation of the extracellular matrix and reduction of blood stream invasion by tumor cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma / drug therapy*
  • Dimethyl Sulfoxide / analogs & derivatives*
  • Dimethyl Sulfoxide / therapeutic use
  • Lung Neoplasms / prevention & control
  • Lung Neoplasms / secondary*
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mice
  • Neoplasm, Residual / drug therapy
  • Organometallic Compounds / therapeutic use*
  • Ruthenium / metabolism
  • Ruthenium / therapeutic use*
  • Survival Analysis

Substances

  • Antineoplastic Agents
  • Organometallic Compounds
  • dimethylsulfoxideimidazoletetrachlororuthenate(III)
  • Ruthenium
  • Dimethyl Sulfoxide